INTRODUCTION
============

This is the 29^th^ report of the Latin American Registry of Assisted Reproduction (RLA) established in 1990 as the first multinational and regional registry of assisted reproductive techniques (ART). Since 2012, reports are published simultaneously in *Reproductive BioMedicine Online* and in *JBRA Assisted Reproduction*, the official journal of the Latin American Network of Assisted Reproduction (REDLARA). Results from previous years can be downloaded from [www.redlara.com](www.redlara.com). This report provides information on utilization/availability, effectiveness, safety and perinatal outcomes of ART treatments initiated between January 1^st^ and December 31^st^, 2017, and babies born up to September 2018.

MATERIALS AND METHODS
=====================

Data on ART were collected from 188 centers in 15 countries in Latin America ([Supplementary Table 1](#t9){ref-type="table"}), covering fresh autologous cycles of in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI); Preimplantation genetic testing (PGT); frozen embryo transfer (FET); oocyte donation (OD) including the transfer of both fresh and frozen/thawed embryos; fertility preservation (FP); and frozen/warmed oocyte cycles, both autologous and heterologous (FTO).

###### 

Assisted reproduction techniques reported in Latin America, 2017

  Country               Centers   FP            FRESH           FET             OD              FTO           Total
  --------------------- --------- ------------- --------------- --------------- --------------- ------------- --------
  **Argentina**         28        842           9,582           4,660           4,533           437           20,054
  **Bolivia**           3         3             391             29              206             25            654
  **Brazil**            63        2,491         20,065          12,282          3,069           1,235         39,142
  **Chile**             10        278           1,778           1,059           710             163           3,988
  **Colombia**          12        69            1,218           449             558             70            2,364
  **Ecuador**           8         116           622             278             317             73            1,406
  **Guatemala**         1         11            128             52              38              0             229
  **Mexico**            38        399           7,222           3,030           4,905           233           15,789
  **Nicaragua**         1         0             118             9               20              1             148
  **Panama**            3         36            468             205             177             29            915
  **Paraguay**          1         16            114             69              37              7             243
  **Peru**              12        976           2,356           1,161           1,545           741           6,779
  **Rep. Dominicana**   2         0             92              21              46              0             159
  **Uruguay**           2         17            751             321             313             17            1,419
  **Venezuela**         4         2             126             60              123             0             311
  **Total**             188       5,256 (5.6)   45,031 (48.1)   23,685 (25.3)   16,597 (17.7)   3,031 (3.2)   93,600

FP, fertility preservation; FRESH, initiated fresh autologous IVF/ICSI cycles; FET, frozen autologous embryo transfer; OD, transfer of fresh or frozen embryos due to oocyte donation; FTO, includes embryo transfer cycles using autologous and donated vitrified-warmed oocytes.

This report includes treatments started between 1 January 2017 and 31 December 2017. Data on pregnancy and perinatal outcomes are obtained from follow-up of cohorts treated during this period.

As part of the accreditation program, all participating institutions agree to have their data registered and published by the RLA. Therefore, no other consent form was requested for the scientific disclosure of these data.

The method of collecting data in 2017 resembles previous years ([@r8]), making results comparable. Definitions used refer to the latest publication of the International glossary on Infertility and Fertility Care ([@r7]). When calculating clinical pregnancy or delivery rates per oocyte pick-up, cases of total embryo freezing were not included in the calculation.

Cumulative live birth rate was calculated, as described by [@r4] from cycles taking place between 2012 and 2017. We considered the first delivery after transfer of either fresh and/or frozen/thawed embryos obtained after a reference oocyte pick up. A personal identification number and date of birth identified each patient. The identification number is not universal in Latin America, so not all patients could be followed and it is also possible that cross border reproductive treatments could partially influence results, but the numbers should be small. Furthermore, only data provided by institutions using a consistent and reproducible ID number were used throughout the study period (2012 and 2017). For the purpose of reporting cumulative births, 166 institutions in 13 countries were included making sure that the use of an identification number remained throughout the study period (Paraguay and Nicaragua were excluded).

In order to test for the effect of age, number of embryos transferred and state of embryo development at transfer on the delivery rate per embryo transfer, logistic regression analysis was performed in both fresh and OD cycles. When appropriate, a chi-squared test was used to analyze independence of categorical variables. A *p*-value less than 0.05 was considered statistically significant.

RESULTS
=======

Participation
-------------

188 centers in 15 countries reported 93,600 ART procedures performed during 2017. This represents more than 70% of centers in the region. The majority of centers were located in Brazil (n=63), followed by Mexico (n=38) and Argentina (n=28) ([Table 1](#t1){ref-type="table"}). In comparison with 2016, 6 centers which had stopped reporting resumed their participation; 9 centers either closed or stopped reporting, mainly in Venezuela and 13 centers were newly incorporated in 2017 contributing with more than 4,900 of the 8,126 new cycles reported in this period.

Size of participating institutions and number of treatment cycles per technique
-------------------------------------------------------------------------------

The 93,600 initiated cycles reported this year (9.5% more than 2016), correspond to the sum of IVF/ ICSI, PGT, FET, OD, FP and FTO. The mean number of initiated cycles by institution was 497.9, with wide variation; 12.8% performed ≤100 cycles; 33.5% between 100 and 300 cycles; 18.1% between 301 and 500 cycles; 20.7% between 501 and 1000 cycles, and 14.9% \>1000 cycles. Overall, the major contributors were Brazil followed by Mexico and Argentina.

Out of 93,600 initiated cycles, 45,031 corresponded to IVF/ICSI (48.1%); 23,685 corresponded to FET (25.3%); 16,597 to OD (17.7%), 5,256 to FP (5.6%), and 3,031 cycles reported as FTO (3.2%) ([Table 1](#t1){ref-type="table"}).

[Figure 1](#f1){ref-type="fig"} provides a detailed description of the sequence of events that need to be considered when looking at outcome of any specific technique (IVF/ICSI, OD, FET, etc.), starting from initiated cycle, cancellations prior to follicular aspiration; aspirations with or without mature oocytes; freeze all oocytes and /or embryos; number of fertilized oocytes or failed fertilization, viability of embryos for transfer or normality of embryos after PGT. It is only after all these events have been considered and adjusted that pregnancy and delivery rates can be calculated with a well-established denominator, being initiated cycle, aspirated cycle, transfer cycle, etc. Needless to say, this detailed description is only possible in a cycle-based registry.

Figure 1Events that affect the outcome of Fresh IVF/ICSI, Oocyte donation (OD), and Frozen/thawed embryo transfer (FET). Latin America, 2017.

ART Utilization in Latin America
--------------------------------

Utilization of ART is expressed as the total number of cycles performed per million inhabitants ([@r3]). Considering that not all cycles performed in every country were reported to the Latin American registry, the best possible estimate of the non-reported cycles was obtained through information provided by regional directors of REDLARA, biologists, clinicians and industry representatives. The magnitude of the estimates, which constitutes a potential source of error, was expressed as degrees of confidence according to [@r2]. If the number of cycles reported to the registry exceeded 95% of the total number of cycles performed in the country, the report was considered complete. If the number of cycles reported to the registry included 64 to 94% of the total or estimated total number of cycles performed in that country, the estimate (number of cycles/million inhabitants) was considered to be of high confidence. When the proportion of cycles reported fell between 33% and 65% of the estimated total number of cycles performed in the country, results were considered of modest confidence; and if less than 33% of all cycles done in a country were reported to our registry, we assumed our numbers had low confidence. As seen in [Figure 2](#f2){ref-type="fig"}, the RLA collects between 70 to 90% of ART cycles performed in most countries in the region, and this is specially so with the major contributors in Latin America. Overall, Argentina and Uruguay, two countries with laws providing universal care to ART have the highest utilization with 535 cycles per million followed by Chile without law but with recent public policies providing partial reimbursement with 349 cycles per million. Brazil is the major contributor in the region but its utilization is still poor.

Figure 2Utilization of ART. Estimated number of initiated cycles per million inhabitants by country in Latin America, 2017

Age distribution
----------------

The mean age of women undergoing IVF/ICSI was 36.9 years (SD 4.57). The majority of cycles were performed in women aged 35 to 39 years (41.7%), followed by women aged ≥40 years (30.5%). Therefore, 72.2% of women using autologous ART were ≥35 years. In the past five years the trend is of an aging population. As seen in [Figure 3](#f3){ref-type="fig"}, there has been a steady drop in the proportion of women aged ≤34, reaching only 27.8% in 2017 while the proportion of women ≥40 have increased from 26.2% in 2013 to 30.5% in 2017.

Figure 3Age distribution of Female partner in IVF/ICSI. Latin America, 2000 - 2017

Outcome of pregnancies and deliveries
-------------------------------------

### Fresh IVF and ICSI cycles

In 2017, there were 45,031 initiated IVF/ICSI. As seen in [Figure 1](#f1){ref-type="fig"}, after discarding aspirations without oocyte or absence of mature oocytes; and 14,694 cases of total embryo freezing; there were 27,464 oocyte retrievals exposed to the chance of achieving pregnancy and 21,836 embryo transfer cycles, generating 7,523 clinical pregnancies (CPR/OPU 27.4%).

Of these pregnancies there were 81 ectopic pregnancies (1.07%), 12 induced abortions and 1,342 miscarriages (17.8%). There were 601 losses to follow-up (7.9%) and 5,487 deliveries. [Table 2](#t2){ref-type="table"} shows the clinical pregnancy rate (CPR) and delivery rate (DR) per oocyte pick-up (OPU) in IVF and ICSI cycles. ICSI represents 85.6% of fresh procedures and there were no differences in CPR or DR per oocyte retrieval between ICSI and IVF (27.3% and 27.7%. and 19.9% and 20.2%, respectively. When calculated by transfer (3359 in IVF and 18477 in ICSI), the differences in the DR per ET in IVF and ICSI, 28.3% and 25.4%, respectively, were higher than in 2016 and in the border of significance (*p*=0.0519 95% CI 0.0048% to 3.17%).

###### 

Clinical pregnancy rate and delivery rate in fresh autologous IVF/ICSI cycles in 2017

  Assisted reproduction technique procedure           Oocyte retrieval^[a](#TFN2){ref-type="table-fn"}^   Clinical pregnancy  rate per oocyte retrieval (%)   Delivery rate per oocyte retrieval (%)
  --------------------------------------------------- --------------------------------------------------- --------------------------------------------------- ----------------------------------------
  **ICSI**                                            23,503                                              6,426 (27.3%)                                       4,688 (19.9%)\*
  **IVF**                                             3,961                                               1,097 (27.7%)                                       799 (20.2%)\*
  **TOTAL**                                           27,464                                              7,523 (27.4%)                                       5,487 (19.97%)
  ***p*-value** **[b](#TFN3){ref-type="table-fn"}**                                                       0.7980                                              0.9856

Oocyte retrieval with at least one mature oocyte, excluding freeze-all cycles

For IVF versus ICSI. (\*) = NS

### Oocyte donation cycles

As seen in [Figure 1](#f1){ref-type="fig"}, in 2017 there were 16,597 initiated cycles, and after removing freeze all cycles (oocytes and embryos) and those without suitable embryos to transfer there were 12,663 transfer cycles. As expected, both CPR and DR per ET much higher (CPR *p*\<0.0001 95% CI 11.32% to 14.08%; DR *p*\<0.0001 95% CI 7.01% to 9.6%) after the transfer of donated oocytes (OD) than in autologous reproduction, reaching 47.2% and 33.4%, respectively. Although CPR in Fresh/OD transfers was significantly higher than FET/OD (p=0.0001 95%CI 1.75% to 5.24%), the DR/ET was similar in both groups ([Table 3](#t3){ref-type="table"}). As expected, compared with autologous transfers, outcome after OD is only marginally affected by the age of the recipient ([Figure 4](#f4){ref-type="fig"}).

###### 

Clinical pregnancy rate and delivery rate by embryo transfer in oocyte donation and FET cycles in 2017

  Assisted reproduction technique procedure   Embryo transfer   Clinical pregnancy per embryo transfer (%)   Delivery rate per embryo transfer (%)
  ------------------------------------------- ----------------- -------------------------------------------- ---------------------------------------
  **Fresh oocyte donation (OD)**              6,433             3,039 (47.2%)\*                              2,148 (33.4%)\*\*
  **Frozen-thawed embryo transfer (OD)**      6,230             2,725 (43.7%)\*                              2,116 (33.9%)\*\*
  **Frozen-thawed embryo transfer (Own)**     22,985            8,696 (37.8%)                                6,539 (28.4%)

(\*) *p*\<0.0001;

(\*\*) *p*=0.5643

Figure 4Delivery rate per embryo transfer according to age of female partner in fresh autologous IVF/ ICSI and fresh and cryopreserved oocyte donation (OD) cycles. Latin America, 2017

### Frozen embryo transfer cycles

In 2017 there were 23,685 FET cycles representing 25.3% of all cycles performed. This represents an increment of more than 20.8% compared with 2016, while the mean number of embryos transferred has remained in 1.9, since 2016 ([Figure 5](#f5){ref-type="fig"}). Of all initiated FET cycles, 700 cycles were discontinued. Reasons for discontinuation were non-survival and/or lack of chromosomally normal embryos (n=507; 2.1%) or abnormal endometrium (n=193; 0.8%). Therefore, out of 22,985 FET cycles, the overall CPR and DR per transfer was 37.8% and 28.4%, respectively ([Table 3](#t3){ref-type="table"}), which is significantly higher than 2016 (*p*=0.0006) and also, significantly higher than the CPR and DR after fresh transfers (*p*\<0.0001). The higher PR and DR in FET compared with Fresh transfers are observed across all number of embryos transferred, especially in SET ([Table 4](#t4){ref-type="table"} and [Supplementary Table 2](#t10){ref-type="table"}).

###### 

Clinical pregnancy rate, delivery rate and gestational order according to the number of embryos transferred in fresh autologous IVF/ICSI in 2017

  Number of transferred embryos   Total embryo transfer   Clinical pregnancy   Deliveries                                                          
  ------------------------------- ----------------------- -------------------- ------------ ------ ------- ------ ------- ------ ----- ------ ---- -----
  1                               5,881                   26.9                 1,481        25.2   1,070   18.2   1,044   97.6   26    2.4    0    0
  2                               12,798                  58.6                 4,902        38.3   3,615   28.3   2,845   78.7   756   20.9   14   0.4
  3                               2,904                   13.3                 1,064        36.6   749     25.8   576     76.9   159   21.2   14   1.9
  ≥4                              253                     1.2                  76           30.0   53      20.9   44      83.0   7     13.2   2    3.8
  Total                           21,836                  100                  7,523        34.5   5,487   25.1   4,509   82.2   948   17.3   30   0.5

Figure 5Trends in the number of frozen/thawed embryo transfer (FET) cycles and mean number of embryos transferred (ET). Latin America, 1996-2017

### Number of embryos transferred, deliveries and multiple births after IVF/ICSI according to the age of women

In women ≤34 years, there were 6,309 fresh transfers. The mean number of embryos transferred was 1.87 (range 1 to 6). In this age group, 23.1% were single embryo transfers (SET), of which 45.6% were elective (eSET). Double embryo transfers (DET) corresponded to 66.8% of transfers, of which 49.6% were elective (eDET). The transfer of three embryos (TET) and 4 or more, was performed in 9.8% and 0.3% of cases.

In women aged 35 to 39 years, there were 9,692 fresh transfers. The mean number of embryos transferred was 1.89 (range 1 to 6). In this age group, 26.4% were SET, of which 28.7% were eSET. DET corresponded to 58.1% of transfers and 39.3% were eDET. The transfer of three embryos (TET) and 4 or more, were performed in 14.9% and 0.6% of cases.

In women ≥40 years of age, there were 5,835 fresh transfers. The mean number of embryos transferred was 1.89 (range 1 to 6). In this age group 31.9% were SET, of which only 12.9% were eSET, 50.9% DET, 24.8% eDET and 14.3% TET; while the transfer of four or more embryos occurred in 2.9% of transfers.

[Table 4](#t4){ref-type="table"} summarizes the overall number of embryos transferred and multiple births after IVF/ICSI. The mean number of embryos transferred was 1.89 (range 1 to 6). There were 5,881 SET (26.9%), and 12,798 DET (58.6%), there were 3,157 transfers with 3 or more embryos (14.5%).

Overall, the CPR and DR per ET reached 34.5% and 25.1%, respectively. In terms of multiple births, of the 5,487 IVF/ICSI deliveries registered, 82.2% were singletons, 17.3% were twins, and 0.5% were triplets or more. Given that SET constitutes a heterogeneous group, [Table 5](#t5){ref-type="table"} further stratifies IVF and ICSI outcome after transferring eSET over oSET (only 1 embryo available for transfer) and eDET over oDET (only 2 embryos available for transfer). There are huge differences both in DR/ET in both eSET and eDET over oSET and oDET; furthermore, the rate of twins and triplets increase with eDET, while eSET by itself does not seem to increase the rate of monozygotic twins.

###### 

Clinical pregnancy rate, delivery rate and gestational order in elective and non-elective SET and DET in fresh autologous IVF/ICSI in 2017

  Number of transferred embryos[\*](#TFN6){ref-type="table-fn"}   Total embryo transfer   Clinical pregnancy   Deliveries                                                         
  --------------------------------------------------------------- ----------------------- -------------------- ------------ ------ ------- ------ ------- ------ ----- ------ --- -----
  oSET                                                            4,243                   72.1                 789          18.6   541     12.8   528     97.6   13    2.4    0   0
  eSET                                                            1,638                   27.9                 692          42.2   529     32.3   516     97.5   13    2.5    0   0
  oDET                                                            7,770                   60.7                 2,408        31.0   1,739   22.4   1,450   83.4   284   16.3   5   0.3
  eDET                                                            5,028                   39.3                 2,494        49.6   1,876   37.3   1,395   74.3   472   25.2   9   0.5

oSET or oDET: non elective single or double embryo transfer; eSET or eDET: elective single or double embryo transfer.

DR/ET: oSET and eSET *p*\<0.0001 95% CI 17.01% to 22.03%.

DR/ET: oDET and eDET *p*\<0.0001 95% CI 13.26% to 16.54%.

### Number of embryos transferred, deliveries and multiple births after OD and FET

[Supplementary Table 3](#t11){ref-type="table"} summarizes the number of embryo transfers and multiple births in OD (fresh and FET), where the mean number of embryos transferred reached 1.86 (range 1 to 5). There were 3,550 SET, which correspond to 28.0% of ET and 1,012 were eSET, representing 28.5% of SET and 8% of all ET/OD. There were 7,409 DET, which correspond to 58.5% of ET, and 2,143 were eDET, representing 16.9% of all transfers in OD.

Overall, the CPR and DR per ET were 45.5% and 33.7%, respectively. Of the 4,264 deliveries registered, 75.0% were singletons, 24.2% twins and 0.8% were triplets and higher. Furthermore, DR/ET was only slightly affected by the age of the oocyte recipient (OR 0.98 95% CI 0.97-0.98) ([Figure 4](#f4){ref-type="fig"}).

In FET cycles the mean number of embryos transferred was 1.71 (range 1 to 5). [Supplementary Table 2](#t10){ref-type="table"} shows there were 8,755 SET, which correspond to 38.1%, and 12,268 DET corresponding to 53.4%. Overall, the CPR and DR per ET reached 37.8% and 28.5%, respectively. Of the 6,539 deliveries registered, 83.3% were singletons, 16.1% were twins, and 0.6% were triplets and higher.

### Total embryo freezing

14,694 cycles of total embryo freezing were reported, 15.4% more than in 2016. On average 4.3 embryos (SD 3.1) were cryopreserved and a mean of 1.7 (1 to 4) embryos transferred. Aspirations followed by total embryo freezing gave rise to 5,856 FET cycles resulting in 1,891 deliveries and a DR/ET of 32.3%; this was higher than the DR/ET of 28.4% observed in non-freeze-all FET cycles (*p*\<0.00001). A second FET attempt was reported in 1,162 cases from the same cohort, with 312 subsequent deliveries, the DR/ET in this attempt was 26.9%. Therefore, adding all transfers from this subset of total embryo freezing, the DR/ET adds to 37.3%. The mean age of women was 35.5±4.5. When stratified by number of embryos transferred, DR/ET was 29.1% in SET and 34.7% in DET.

### Influence of stage of embryo development at transfer

Overall, 58.2% of ET were performed at the blastocyst stage, representing a 17% increment over 2016. The proportion of blastocysts transfers in FET (70.8%) almost doubled the proportion in Fresh IVF/ICSI (37.5%) This is important to consider when comparing outcome after fresh and frozen thawed transfers. In OD cycles (both fresh and frozen), the proportion of blastocyst transfers reached 69.4% which is 30% more than in 2016. Blastocyst transfer was always associated with higher DR when compared with cleavage-stage embryos, irrespective of whether fresh or frozen and the number of embryos transferred.

In IVF/ICSI, the DR after 8,185 blastocyst transfers was 31.16% compared with 21.77% after the transfer of 13,629 cleaving embryos (*p*\<0.0001). In OD, the DR/ ET was 37.1% in blastocyst transfers and 25.9% in cleaving embryo (*p*\<0.0001); and in FET, the proportion was 31.9% and 20.0%, respectively (*p*\<0.0001).

### Preimplantation genetic testing (PGT)

The RLA registers PGT-M and PGT-A together. 132 centers reported these procedures in 5.193 fresh cycles (11.8% of OPU); 2.353 using frozen-thawed embryos (8.1% of transfers) and 571 (8.9% of transfers) in OD. The mean age of women undergoing PGT was 38.0 (SD 4.2) among fresh cycles and 38.1 (SD 4.3) in FET.

In fresh autologous cycles, the mean number of normal embryos was 1.1 over a mean of 3.1 (SD 2.3) embryos biopsied. In FET cycles, the mean number of normal embryos was 1.9 over a mean of 3.4 biopsied. In OD, the mean number of normal embryos increased to 2.7 over a mean of 4.8 embryos biopsied. The DR/ET was 23.9% in fresh IVF/ICSI, 37.9% in FET and 43.6% in OD.

### Miscarriage

Miscarriage rate in 7,523 pregnancies resulting from autologous fresh embryo transfer and 8,696 pregnancies of FET were 17.8% and 17.4%, respectively. As expected, miscarriage rate in a total of 3,039 OD was lower both in fresh transfers (15.6%) and in frozen/thawed OD (15.0%). Furthermore, in 672 cases of OD using FTO, miscarriage rate was also 15.0% The miscarriage rate using PGT reached 12.3% in pregnancies after FET and 14.8% in OD-FET. [Table 6](#t6){ref-type="table"} provides information on the effect of PGT on miscarriage rate after FET in different age groups. When comparing miscarriage after autologous FET with and without PGT, the rate of miscarriage is significantly diminished when PGT is performed in women ≥40 from 23.7% to 9.3% (*p*\<0.0001); the difference is also significant in women age 35 to 39, but in women \< 35, PGT does not seem to lower the chances of miscarriage (*p*\>0.3989). Furthermore, in 250 pregnancies resulting from PGT performed in FET/OD, there were 37 miscarriages (14.8%) compared with a miscarriage rate of 15.0% in FET/OD without PGT.

###### 

Effect of PGT on miscarriage rate after FET in different age groups

             FET with PGT   FET without PGT    
  ---------- -------------- ----------------- -------------
  \<35       12.8%          15.3%             *p*=0.3989
  35 to 39   13.9%          17.8%             *p*=0.0724
  \>39       9.3%           23.7%             *p*\<0.0001

### Fertility preservation (FP)

A total of 5,256 initiated cycles for FP were reported in 2017 representing 20% increase over 2016. The mean age of women was 36.1 years (≤34=27.1%, 35-39=48.7% and ≥40=24.2%). No oocytes were available for freezing in 247 follicular aspirations (4.7%). The mean number of oocytes cryopreserved was 7.5 with huge variations depending on the age of women (≤34=10.2, 35-39=7.3, and ≥40=4.9). In cases where the indication for FP was recorded, the majority were related to the desire to postpone pregnancy (3,024 cases representing 60.4%), while cancer-related factors were reported in 343 cases (6.8%); risk of premature ovarian insufficiency in 289 (5.8%) cases and other reasons in 1,353 cases (27.0%). More than 10 oocytes were cryopreserved in only 30% of women expressing the desire to postpone fertility, 39% in women having cancer and as expected, the proportion dropped to only 6% in women with risks of premature ovarian insufficiency.

Cumulative delivery rate (CDR)
------------------------------

We were able to follow up the outcome of fresh embryo transfers and their consecutive FET in 47,492 patients between 2012 and 2017. This cohort included only women having surplus frozen embryos resulting from their fresh transfer, and only the first delivery after either fresh or frozen transfers. Taking all patients together, the DR/ET increased from 37.6% after fresh embryo transfer to a cumulative rate of 43.5% (RR 1.104; 95% CI 1.09 to 1.12; *p*\<0.0001). The cumulative DR per ET stratified by the age of female partner at the time of OPU is shown in [Figure 6](#f6){ref-type="fig"}. The increment in DR when adding FET over fresh transfers was inversely correlated to the age of the female partner. The OR for delivery was 1.3 in women \<35 years (95% CI 1.2 to 1.3); 1.2 in women 35 to 39 (95% CI 1.1 to 1.3) and 1.1 in women \>39 (95% CI 1.1 to 1.3).

Figure 6Cumulative delivery rate per embryo transfer (cDR/ET) and delivery rate per fresh embryo transfer (DR/ET) according to the age of female partner in women with surplus frozen embryos resulting from their fresh transfer. Latin America, 2017.

### Perinatal outcome and complications

[Table 7](#t7){ref-type="table"} summarizes perinatal mortality. Data was available from 16,760 births and 20,093 babies born. The perinatal mortality increased from 9.4‰ births in 13,532 singletons, to 25.3‰ in 6,250 twins and 63.3‰ in 311 triplets and higher. With 1911 more babies born than in 2016, multiparity increased perinatal death in similar proportion to previous years.

###### 

Perinatal mortality according to gestational order in 2017

                                Singleton   Twin    ≥ Triplets
  ----------------------------- ----------- ------- ------------
  **Livebirth\***               13,532      6,250   311
  **Stillbirth**                57          63      5
  **Early neonatal death**      71          99      16
  **Perinatal Mortality\*\***   9.4‰        25.3‰   63.3‰

(\*) Early neonatal death are excluded (\*\*) Perinatal Mortality = (stillbirth + early neonatal death) / (livebirth + stillbirth + early neonatal death)

(\*\*) Perinatal Mortality = (stillbirth + early neonatal death) / (livebirth + stillbirth + early neonatal death)

Gestational age at delivery was reported in 14,804 deliveries (87.2% of all deliveries). The mean gestational age at delivery was 37.7 (SD 2.3) weeks in singletons, 35.2 (SD 2.9) weeks in twins, and 31.7 (SD 2.9) weeks in triplets and higher. The overall risk of preterm birth (gestational weeks 22-36) increased from 9.5% in singletons, to 64.3% in twins, and 97.9% in triplets and higher. Furthermore, the risk of very preterm birth (gestational weeks 22-27) increased from 0.81% in singleton to 3.0% in twins and to 9.3% in triplets and higher. [Table 8](#t8){ref-type="table"} shows the weight of babies born after fresh, frozen/thawed and fresh OD treatments, according to the order of gestation. As it has been reported previously ([@r5]; [@r6]), the weight of singletons born after FET (3,164±539) is significantly higher than babies born after fresh transfer (3,075±566; *p*\<0.0001). A similar situation occurs after the birth of twin.

###### 

Gestational age and weight at birth acccording to gestational order in 2017

  ART procedure                    Singleton            Twin              ≥Triplets                                                   
  -------------------------------- -------------------- ----------------- -------------------- ----------------- -------------------- -----------------
                                   Weeks of gestation   Weight grams±SD   Weeks of gestation   Weight grams±SD   Weeks of gestation   Weight grams±SD
  **Fresh autologous IVF/ICSI**    37.73                3,074.5±565.5     35.06                2,246.4±568.3     31.33                1,468.1±514.2
  **Autologous FET**               37.83                3,164.3±538.9     35.35                2,370.2±559.7     31.97                1,674.7±574.6
  **Fresh and frozen/thawed OD**   37.36                3,008.4±582.7     35.13                2,292.2±571.6     32.07                1,641.6±464.3

DISCUSSION
==========

This is the 29^th^ report on ART procedures performed in Latin America. The number of new centers reporting to RLA continues to grow. Between 2016 and 2017,13 new centers were incorporated contributing to almost 5000 of the 8,126 new cycles reported in this period (8.7%). As seen in [Figure 2](#f2){ref-type="fig"} the majority of the 15 countries voluntarily report around 70% to 90% of the cycles performed in each country. This constitutes a noteworthy commitment of centers, which have freely kept reporting year after year for nearly 30 years. The rise in the number of initiated cycles, results in part by a 20% increment in FP, 20.8% increment in FET cycles and 15.4% rise in freeze all cycles. However, in spite of this, the drop in the proportion of twins and high order multiples has been very poor.

The mean ART utilization in 12 countries where data is reliable ([Figure 2](#f2){ref-type="fig"}) is only 221 initiated cycles/million population which is very much under the threshold of 1,500 cycles per annum per million inhabitants proposed by the ESHRE Capri Group, in order to fulfil the needs of a population ([@r3]). Utilization of health services is closely associated with economic affordability. Argentina and Uruguay with laws providing universal coverage for infertility treatments have increased their utilization rate reaching 535 cycles /million inhabitants; Chile, with partial public coverage is also increasing its utilization rate but at a slower pace with only 349 cycles /million; and Brazil the largest contributor in the region, with proportionally little public support, provides less than 200 cycles/million population. This relationship confirms the importance of financial affordability in the utilization of ART. In countries with strong economic inequalities, the numbers of couples who can afford treatment are few. Public policies providing partial or complete financial support to persons requiring ART are pivotal in order to increase utilization and decrease the burden generated by infertility *per se*, as well as the burden which results from lack of access in a society with profound socio-economic disparities.

The reporting of efficacy in ART can be presented in many different ways. While there is overall agreement, that a proper outcome for ART is delivering a healthy livebirth, the main difficulty lies in what to use as denominator and how to reach international agreement in order to compare results from different latitudes. By incorporating [Figure 1](#f1){ref-type="fig"}, we have tried to acknowledge this difficulty. If the chosen denominator is an "initiated cycle", the freeze all cycles need to be removed because those women were not exposed to the risk of pregnancy. That accounts for 14,694 out of 45,031 fresh IVF and ICSI cycles, which leaves us with 30,337 initiated cycles where women had the real intention of becoming pregnant in that treatment. However, for the various reasons mentioned in [Figure 1](#f1){ref-type="fig"}, only 21,836 cycles/women (72%) were in fact exposed to the chance of a livebirth after having at least one embryo transferred. This is very much dependent on the age and overall health of the population treated. In cases of young and healthy oocyte donors (OD) the proportion of dropouts due to lack of oocytes or abnormal embryos is much lower. If the freeze all cycles are removed in OD, there were 12,663 transfers which represent 94.9% of the initiated cycles exposed to the chance of pregnancy. All these clinical and biological variables need to be considered both for counseling patients and for the purpose of making results comparable.

When using large data base to provide evidence-based counselling to patients, the denominator must be initiated cycle after discarding freeze all cycles. On the other hand, if the objective is to compare the efficacy of different treatment interventions such as fresh over FET transfers or freeze all over FET that results from a failed fresh cycle, the preferred denominator is "embryos transferred". When comparing DR after fresh transfers in [Table 4](#t4){ref-type="table"} with frozen /thawed transfers in [Supplementary Table 2](#t10){ref-type="table"} it is evident that FET is more efficient in both SET and DET. However, the question is whether they are comparable considering that only 37.5% of fresh transfers were blastocysts compared with 70.8% in FET. When efficacy is measured after transferring only blastocyst, the DR/ET was almost identical; 31.16% in fresh and 31.9% in FET. One can also be tempted to assume that the most efficient option is the delayed transfer after a freeze all cycle. In fact, after 5,856 FET originated from a freeze all procedure, the overall DR/ET was 32.3% compared with an overall 28.4% FET following a fresh cycle, with similar proportion of blastocysts transferred. This difference is even greater after SET (29.1% in freeze all and 25.5% in FET after a fresh cycle). Again, these two are difficult to compare. Firstly, the mean age of women during the fresh cycle that originated FET was 36.9 years while the mean age of women having freeze all was 35.5. Secondly, we must assume that in the case of a FET cycles that follows a fresh attempt, the best embryos were used in the fresh attempt and the woman was not pregnant, so the cohort of embryos left for FET from those women have a negative selection, while in the case of freeze all cycles, the best embryo is selected in the first attempt.

What can reasonably be said is that the transfer of frozen thawed embryos does not jeopardize the chances of becoming pregnant and delivering a term livebirth as seen in [Supplementary Table 2](#t10){ref-type="table"} and [Table 8](#t8){ref-type="table"}.

Another factor worth considering when analyzing efficacy is that providing global results for SET or DET can be misleading. As seen in [Table 5](#t5){ref-type="table"} only 27.9% of SET were eSET and only 39.3% of DET were eDET. The differences in DR/ET are highly significant when the embryo selected for transfer belongs to a larger cohort of embryos available (eSET, eDET) instead of transferring one or two embryos because there were no more embryos available for transfer (oSET, oDET). The DR/ET in 1,638 eSET reached 32.3% with 2.5% of monozygotic twins. On the other hand, the transfer of eDET increased DR by only 5% over eSET, but generated 25% of twins and 0.5% triplets with severe impact in preterm births and perinatal mortality ([Tables 7](#t7){ref-type="table"} and [8](#t8){ref-type="table"}).

When examining cumulative livebirths in our cohort of 47,492 patients followed between 2012 and 2017 ([Figure 6](#f6){ref-type="fig"}). All patients were selected because they had an elective transfer during their fresh cycle, in fact, that was the reason to include them in the study of cumulative livebirths. When these curves were compared with the DR/ET in all fresh transfers in 2017 ([Figure 4](#f4){ref-type="fig"}) the differences are huge and the results of fresh transfers in the cumulative group more closely resemble those of the fresh transfers in oocyte recipients which are mostly women with numerous embryos for transfer.

Preimplantation genetic testing (PGT) is also increasing in Latin America. Overall, 8,117 procedures were reported by 132 out of 188 institutions (ten more institutions and 2,970 more procedures than the previous year). When examining the efficacy of PGT and taking into consideration the older population treated (mean age: 38.1±4.3 years), the DR/ET, was significantly higher when comparing 1,745 cases of FET with PGT (37.9%) with 6,539 of FET without PGT (28.5%) (*p*\<0.0001). The number of cases in OD and fresh transfers were too small to allow for meaningful comparisons. Furthermore, miscarriage took place in 17.6% of 16.219 pregnancies after fresh and frozen/thawed autologous cycles. This dropped to 12.8% in 845 pregnancies with PGT. In order to see the relative benefit of PGT in different age categories, miscarriage was compared with and without PGT in a standard group of only FET cycles. As seen in [Table 6](#t6){ref-type="table"}, there is clear benefit with PGT in women ≥40, but the benefit in younger women, although consistent, does not reach mathematical significance. The numbers are still relatively low but more and more women and men in Latin America are seeking for the illusion of certainty in delivering "normal" offspring, even in cases of OD where surprisingly 3.9% of cycles used PGT.

The concept of fertility preservation deserves special attention. When examining the data gathered in women vitrifying oocytes in order to postpone gestation, 73% were (35 (24% (40 years), and 70% of these women had less than 10 oocytes collected. This implies that a large proportion of women are living with the unrealistic expectation of becoming mothers when they so wish. The concept of fertility preservation should perhaps be replaced by oocyte preservation and at the same time, especially in emerging economies where fertility is delayed due to heavy academic or work environments, advocacy groups should contribute to educating young women and simultaneously facilitate the establishment of public policies to provide gamete preservation at younger age.

Latin America has much room to improve. Starting with increasing access to treatment, which shall not only decrease the burden of disease, but also bridge the abysm between the rich and the poor who suffer from infertility. However, independently from many related considerations, multiple births is still a problem that needs to be dealt with on a global basis considering that of all babies born in the region, only 66.9% were singletons, while 31.4% twins, and 1.6% triplets and higher. The mean number of embryos transferred has remained quite stable in 1.9, however there are huge differences among countries in the region. While Argentina, Uruguay and Bolivia transfer a mean of 1.6 embryos, the mean number of embryos transferred in Brazil and Mexico, the two major contributors, are 2.0 and 2.2 embryos, respectively.

There is indirect evidence that when access to ART is facilitated, the number of SET cycles increase, and "success" is procured as the result of cumulative events such as fresh plus frozen transfers ([@r1]). Instead, when women have only one chance in their life, the number of embryos transferred increase in order to secure pregnancy in that unique event. Nonetheless, after a critical look at these regional data, there are numerous improvements to be made in order to increase the proportion of blastocyst transfers, especially in young women, facilitating a higher proportion of eSET. Also, the good results with FET are expressed in the cumulative livebirth rates, which for young women can be as high as 50%. Any series of actions directed at facilitating access to treatment, and at the same time implementing strict quality control systems in the laboratories in order to ensure efficient long-term embryo culture and good cryopreservation techniques should be pivotal in lowering the number of embryos needed to achieve birth. The 32.3% birth rate after fresh eSET is indeed reassuring and should become a standard especially considering that when 2 embryos are electively transferred, the rise in births is only 5%, while there is a 10-fold rise in multiple births with severe impact in preterm births and perinatal mortality.
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###### 

List of centers by country, reporting to the Latin American Registry of ART in 2017.

  ---------------------- --------------------------------------------------------------------------------------------------
  ARGENTINA              
  •                      Servicio de Medicina Reproductiva, Instituto Gamma
  •                      Instituto de Fertilidad Asistida
  •                      Centro de Estudios en Ginecología y Reproducción (CEGYR)
  •                      Centro de Salud Reproductiva (CER)
  •                      Instituto Tersoglio
  •                      Centro Integral de Ginecología, Obstetricia y Reproducción (CIGOR)
  •                      Centro de Investigaciones en Medicina Reproductiva (CIMER)
  •                      Centro de Medicina Reproductiva Bariloche, Fertility Patagonia
  •                      Centro de Estudios en Reproducción y Procedimientos de Fertilización Asistida (CRECER)
  •                      FECUNDITAS
  •                      FERTILAB
  •                      GESTAR
  •                      Centro de Reproducción Fertilequip
  •                      Fertya
  •                      Hospital de Clínicas
  •                      FECUNDART
  •                      Centro de Reproducción, servicio de Ginecología Hospital Italiano
  •                      Mater, Medicina Reproductiva
  •                      Nascentis, Medicina Reproductiva
  •                      HALITUS, Instituto Médico
  •                      Instituto Médico de Ginecología y Fertilidad PREFER
  •                      PREGNA, Medicina Reproductiva
  •                      Programa de asistencia reproductiva PROAR
  •                      PROCREARTE
  •                      Fertilidad San Isidro
  •                      SARESA, Salud reproductiva Salta
  •                      SEREMAS
  •                      VITAE, Medicina Reproductiva
                         
  BOLIVIA                
  •                      CENALFES
  •                      Instituto de Salud Reproductiva (ISARE)
  •                      EMBRIOVID, centro integral de reproducción y especialidades médicas
                         
  BRAZIL                 
  •                      ANDROLAB, Clinica y Laboratorio de Reproducción Humana y Andrología
  •                      ANDROFERT, Centro de Referencia en Reproducción Masculina 
  •                      FERTIVITRO, Centro de Reproducción Humana
  •                      BIOS, Centro de Medicina Reproductiva
  •                      FIV-MED
  •                      Centro de Medicina Reproductiva, Clinica Geare
  •                      VIDA, Centro de Fertilidad
  •                      Clinica FERTWAY
  •                      NASCER, medicina reproductiva ltda.
  •                      ORIGINARE, Centro de Investigación y Reproducción Humana
  •                      CLINIFERT, Centro de Reproducción Humana
  •                      CONCEPTUS, Centro de Reproducción Asistida de Ceara
  •                      CONCEBER, Centro de Medicina Reproductiva
  •                      Clinica Origen
  •                      Clinica Pro-Genesis
  •                      Centro de reproducción humana CONCEPTION
  •                      Centro de Reproducción Humana MONTELEONE
  •                      Fértile Diagnósticos
  •                      CEERH, Centro especializado en Reproducción Humana
  •                      Embrios, centro de reproducción humana
  •                      EMBRYOLIFE, Instituto de Medicina Reproductiva
  •                      Centro de Reproducción Humana, Endoscopia y Medicina Fetal de Bahía (CENAFERT)
  •                      Instituto VERHUM
  •                      Clinica FERTIBABY BH
  •                      Fertilcare, Medicina reproductiva
  •                      FECUNDA, Reproducción Humana
  •                      FELICCITA, Instituto de Fertilidad Ltda.
  •                      HUMANA, Medicina Reproductiva
  •                      FERTILITY, Centro de Fertilización Asistida de Campo Grande
  •                      FERTILITY, Centro de Fertilización Asistida
  •                      FERTIL Reproduccion Humana
  •                      REPROFERTY
  •                      FERTICLIN, Clínica de Fertilidad Humana
  •                      GENESIS, Centro de Asistencia en Reproducción Humana 
  •                      Clinica Genics, medicina reproductiva y genómica
  •                      FERTIPRAXIS, Centro de Reproducción Humana 
  •                      GERA, Grupo de endoscopia y Reproducción Asistida
  •                      Clinica GERAR VIDA
  •                      Instituto de Saude Da Mulher, Cegonha Medicina Reproductiva
  •                      IVI Sao Paulo, Chedid Grieco S.A.
  •                      HUMANA (PRIMORDIA, Medicina Reproductiva Huntington RJ)
  •                      Hospital de Clínicas de Riberao Preto
  •                      HUNTINGTON Campinas
  •                      HUNTINGTON, Centro de Medicina Reproductiva (Sao Paulo)
  •                      JULES WHITE, Centro de Medicina Reproductiva
  •                      HUNTINGTON Vila Mariana
  •                      Ideia Fertil
  •                      IMR, Instituto de Medicina Reproductiva e Fetal
  •                      Servicio de Reproducción Humana Del Hospital y Maternidad Santa Johana
  •                      Life reproducción humana
  •                      FERTILITAT, Centro de Medicina Reproductiva
  •                      Clínica MATRIX
  •                      Pro-criar Monte Sinaí
  •                      Centro de Reproducción Humana Nilo Frantz
  •                      Clínica ORIGEN
  •                      Procriar, Clinica de Fertilización Asistida, Blumenau
  •                      Clínica PRO-CRIAR, Medicina Reproductiva BH
  •                      Clínica PRO NASCER
  •                      Clinica de Reproducción PROSER SS
  •                      Centro de Reproducción Humana De San Jose de Rio Preto
  •                      GENESIS, Centro de Reproducción Humana
  •                      Centro de Reproducción Humana Prof. Franco Junior
  •                      Centro de Ensino y Pesquisa en Reproducción Asistida (Centro de Rep. Asist. Hospital Da ASA SUL)
                         
  CHILE                  
  •                      UMR Clínica de la Mujer Antofagasta
  •                      Centro de Estudios Reproductivos (CER)
  •                      Unidad de Medicina Reproductiva, Clínica Alemana
  •                      Unidad de Medicina Reproductiva, Clínica las Condes
  •                      Unidad de Medicina Reproductiva, Clínica de la Mujer
  •                      UMR clínica Indisa
  •                      Programa e Fertilización Asistida I.D.I.M.I.
  •                      Clínica Monteblanco
  •                      Centro de Fertilidad y Medicina Reproductiva Concepción S.A.
  •                      Centro de reproducción humana, Valparaiso
                         
  COLOMBIA               
  •                      Centro FECUNDAR, Cali
  •                      Unidad de fertilidad del Coutry ltda. CONCEPTUM
  •                      Asociados en Fertilidad y Reproducción Humana
  •                      FERTIVIDA
  •                      Clinica Machicado SAS
  •                      Centro Médico IMBANACO
  •                      Instituto de Fertilidad Humana S.A.S. (INSER)
  •                      IN SER, Instituto Antioqueño de Reproducción
  •                      Procrear
  •                      Profamilia Fertil
  •                      Unidad de Fertilidad, Procreación Medicamente Asistida
  •                      Union temporal IN SER eje cafetero
                         
  ECUADOR                
  •                      Clínica de Medicina Reproductiva BIOGEPA
  •                      Centro Ecuatoriano de reproducción humana
  •                      Clínica INFES
  •                      Instituto Nacional de Investigación de Fertilidad y Esterilidad (INNAIFEST)
  •                      Instituto de Reproducción Humana Guayaquil
  •                      CONCEBIR, Unidad de Fertilidad y Esterilidad 
  •                      Unidad de Fertilidad Hospital Alcívar
  •                      PROCREAR
                         
  GUATEMALA              
  •                      Centro de Reproducción Humana S.A. (CER)
                         
  MEXICO                 
  •                      Centro de Diagnóstico Ginecológico
  •                      Biofertility Center
  •                      URA, Unidad de reproducción asistida de Hispital CIMA Hermosillo 
  •                      Centro de Cirugía Reproductiva y Ginecología, Unidad de Fertilización In Vitro (REPROGYN)
  •                      Instituto de Innovación Tecnológica y Medicina Reproductiva CITMER
  •                      Instituto para el estudio de la Concepción Humana IECH
  •                      Centro de Reproducción Asistida del Hospital Español (HISPAREP)
  •                      Centro de Reproducción Asistida del Occidente
  •                      Centro de Reproducción Asistida de Saltillo
  •                      Centro Universitario de Medicina Reproductiva
  •                      Fertility Center Cancún
  •                      Genesis Centro de Fertilidad (Culiacan)
  •                      Ginecología y Reproducción Asistida GYRA
  •                      Grupo de reproducción y genética AGN y asociados
  •                      Instituto para el estudio de la concepción humana de Baja California
  •                      Instituto Mexicano de Alta Tecnología Reproductiva S.C. (INMATER)
  •                      Instituto de medicina reproductiva del Bajío IMER, sede Guadalajara
  •                      Instituto IMER de Tijuana
  •                      Instituto Médico de la mujer (RED CREA)
  •                      Instituto de Ciencias en Reproducción Humana, sede Guadalajara
  •                      Instituto de Ciencias en Reproducción Humana, sede Matamoros
  •                      Centro especializado para la atención de la mujer (CEPAM)
  •                      INGENES DF
  •                      INGENES Guadalajara
  •                      Ingenes Monterrey
  •                      Instituto de Ciencias en Reproducción Humana (VIDA), sede León
  •                      Medica Fertil, Querétaro
  •                      Instituto de ciencias en reproducción humana del Sureste (Vida Merida)
  •                      Clinica Nascere
  •                      Centro de Medicina Reproductiva FILIUS
  •                      Plenus, Reproducción Asistida
  •                      PROGEN, Reproducción asistida y medicina fetal
  •                      Centro de Reproducción Asistida Santa Fe SA de CV (PRONATAL)
  •                      Clinica de Infertilidad y reproducción asistida de Toluca SA de CV
  •                      Centro especializado en esterilidad y Reproducción Humana (CEERH)
  •                      Instituto de Ciencias en reproducción humana VIDA, ciudad de Mexico.
  •                      VILTIS
  •                      Vida, Instituto de Reproducción Humana del Noroeste, Tijuana
                         
  NICARAGUA              
  •                      Centro de Fertilidad de Nicaragua
                         
  PANAMA                 
  •                      IVI Panamá S.A.
  •                      Centro de reproducción Punta Pacífica
  •                      Instituto de salud femenina
                         
  PARAGUAY               
  •                      Neolife, Medicina y cirugía reproductiva
                         
  PERU                   
  •                      Clínica CEFRA, Centro de Fertilidad y Reproducción Asistida
  •                      CERFEGIN
  •                      Centro de Fertilidad y Ginecología del Sur (CFGS)
  •                      Clinica de fertilidad del norte, Clinifer de Chiclayo
  •                      FERTILAB, Laboratorio de Reproducción asistida
  •                      Inmater, Clinica de fertilidad
  •                      Instituto de Reproducción de la Clinica Ricardo Palma
  •                      Clinica Miraflores
  •                      Nacer
  •                      Grupo Pranor, Clínica CONCEBIR
  •                      Grupo Pranor, Instituto de Ginecología y Reproducción
  •                      Pranor, laboratorio de medicina reproductiva sede trujillo
                         
  REPUBLICA DOMINICANA   
  •                      Instituto de reproducción y ginecología del Cibao (IREGCI)
  •                      PROFERT
                         
  URUGUAY                
  •                      Centro de Esterilidad Montevideo (CEM)
  •                      Centro de Reproducción Humana del Interior
                         
  VENEZUELA              
  •                      FERTILAB
  •                      EMBRIOS, Centro de Fertilidad y Reproducción Humana, Hospital de Clínicas de Caracas
  •                      Instituto Venezolano de Fertilidad
  •                      Laboratorios In Vitro de Venezuela
  ---------------------- --------------------------------------------------------------------------------------------------

###### 

Clinical pregnancy rate, delivery rate and gestational order according to the number of embryos transferred in FET in 2017.

  Number of transferred embryos   Total embryo transfer   Clinical pregnancy   Deliveries                                                           
  ------------------------------- ----------------------- -------------------- ------------ ------ ------- ------ ------- ------ ------ ------ ---- -----
  1                               8,755                   38.1                 3,000        34.3   2,229   25.5   2,195   98.5   34     1.5    0    0.0
  2                               12,268                  53.4                 4,968        40.5   3,775   30.8   2,883   76.4   873    23.1   19   0.5
  3                               1,872                   8.1                  702          37.5   518     27.7   361     69.7   138    26.6   19   3.7
  ≥4                              90                      0.4                  26           28.9   17      18.9   11      64.7   5      29.4   1    5.9
  Total                           22,985                  100.0                8,696        37.8   6,539   28.4   5,450   83.3   1050   16.1   39   0.6

###### 

Clinical pregnancy rate, delivery rate and gestational order according to the number of embryos transferred in fresh and frozen oocyte donation cycles in 2017.

  Number of transferred embryos   Total embryo transfer   Clinical pregnancy   Deliveries                                                            
  ------------------------------- ----------------------- -------------------- ------------ ------ ------- ------ ------- ------ ------- ------ ---- -----
  1                               3,550                   28.0                 1,427        40.2   1,033   29.1   1,013   98.1   19      1.8    1    0.1
  2                               7,409                   58.5                 3,499        47.2   2,585   34.9   1,803   69.7   772     29.9   10   0.4
  3                               1,674                   13.2                 825          49.3   637     38.1   376     59.0   239     37.5   22   3.5
  ≥4                              30                      0.3                  13           43.3   9       30.0   7       77.8   2       22.2   0    0.0
  Total                           12,663                  100.0                5,764        45.5   4,264   33.7   3,199   75.0   1,032   24.2   33   0.8
